All of the classes of drugs approved for the treatment of PAH, including PDE5 inhibitors and sGC stimulators, can affect pulmonary arterial tone, but are also believed to impact disease progression by inhibiting pathological vascular remodeling (Rubin, 2013). This evidence concerns the gene PDE5A and pulmonary arterial hypertension.